Skip to main content
OpenTrials
Completed

NCT Number: NCT04670328

Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

17 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

FMH college of medicine and dentistry

Lahore, Punjab Province, 54000, Pakistan

About this study

Objective:

COVID-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. Patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. These hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Material and Method:

This was a retrospective study, conducted in Department of Pathology and Department of medicine, FMH college of Medicine and Dentistry from May 2020 to July 2020. Total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. Hematological parameters were compared in mild, moderate, severe and critical disease group. Continuous variables were analyzed by using non parametric, Kruskal Wallis test while categorical variables were analyzed by chi-square test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed cases of covid-19 disease
  • Both genders
  • 17 to 75 year age

Exclusion criteria

  • known case of chronic liver disease
  • known hematological diseases were excluded

Treatment and study plan

not required

Diagnostic Test

Diagnostic tests( hematological parameters) were assessed.

Primary outcomes

  1. complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio

    Time frame: 3 months

    disease severity was assessed on basis of hematological parameters.

Secondary outcomes

  1. PT, APTT and D-dimer

    Time frame: 3 months

    improvement in PT, APTT and D-dimer levels were assessed

Other outcomes

  1. LDH, serum ferritin level

    Time frame: 3 months

    improvement in LDH and were assessed

Sponsors and collaborators

Lead sponsor

FMH College of Medicine and Dentistry

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 17, 2020
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.